GENE ONLINE|News &
Opinion
Blog

2020-09-22| Special

Spotlight: Cannabidiol (CBD) Based Medication Heralds New Promise in Neurological Therapies

by GeneOnline
Share To
Among the 100 or so phytocannabinoids that have been identified in the Cannabis sativa herb, delta 9-tetrahydrocannabinol (THC) and cannabidiol (CBD) have been explored the most for pharmacological use. Although 33 states have approved the use of cannabis in the U.S. for medicinal purposes, the U.S. Drug Enforcement Administration recognizes it as a Schedule I drug.

This has impeded the use of cannabis in clinical research, potentially obscuring physicians and nurses about its safety, efficacy, and dosage for pharmaceutical applications through rigorous double-blinded, placebo-controlled studies. Besides, cannabinoid-containing substances obtained for research purposes are not chemically or physically representative of the legal cannabis market.

GO Prime with only $1.49 now

LATEST
Ascletis Announces U.S. IND Filing of Oral RdRp Inhibitor Drug Candidate ASC10 for COVID-19
2022-07-05
Breakthrough Zebrafish Genome Database Now Available
2022-07-05
WuXi Biologics Adds Microbial Fermentation to CDMO Offering in Hangzhou
2022-07-05
Sanofi Launches Nonprofit Brand To Distribute Medicines to Low-Income Countries
2022-07-05
As Private Equity Sale Becomes Less Likely, Novartis May Gravitate Towards Sandoz Spinoff
2022-07-04
Ascletis Begins Study of PD-L1 Antibody Candidate Against HIV
2022-07-04
Akebia Therapeutics Gains $55M Following Deal Termination by Otsuka Pharmaceutical
2022-07-04
EVENT
2022-07-27
BIO Asia–Taiwan 2022
Online and on-side
2022-08-03
BIOPLUS-INTERPHEX KOREA
Seoul
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-21
CSCO Educational Book 2022
Xiamen
2022-09-21
RESI Boston
Boston
2022-09-26
Human Gene Therapy Conference
Australia
Scroll to Top